Our results show that, although in vivo growing A375 melanoma cells preferentially overexpress different Bcl-2-related proteins (as compared to cultured A375 cells), in vivo targeting of Bcl-2 leads to growth inhibition and sensitization to combined chemoradiotherapy. Here, BCL2 is linked to melanoma.